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Abstract: Drug-like molecules are known to contain many different building blocks with great
potential as pharmacophores for drug discovery. The continued search for unique scaffolds in
our laboratory led to the isolation of a novel Ghanaian soil bacterium, Streptomyces sp. MA37.
This strain produces many bioactive molecules, most of which belong to carbazoles, pyrrolizidines,
and fluorinated metabolites. Further probing of the metabolites of MA37 has led to the discovery of a
new naphthacene-type aromatic natural product, which we have named accramycin A 1. This molecule
was isolated using an HPLC-photodiode array (PDA) guided isolation process and MS/MS molecular
networking. The structure of 1 was characterized by detailed analysis of LC-MS, UV, 1D, and 2D
NMR data. Preliminary studies on the antibacterial properties of 1 using Group B Streptococcus
(GBS) produced a minimum inhibitory concentration (MIC) of 27 µg/mL. This represents the first
report of such bioactivity amongst the naphthacene-type aromatic polyketides, and also suggests the
possibility for the further development of potent molecules against GBS based on the accramycin
scaffold. A putative acc biosynthetic pathway for accramycin, featuring a tridecaketide-specific type
II polyketide synthase, was proposed.
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1. Introduction
Natural products continue to provide highly diverse chemical scaffolds, which have facilitated
the research and development of many currently marketed drugs and viable clinical candidates [1].
Excellent examples of these natural scaffolds that have aided in the design of several compound libraries
include the β-lactams (penicillin G), macrolactones (erythromycin), glycopeptides (vancomycin),
tetracylines, and modified nucleosides [1,2].
Bacterial aromatic polyketides are prolific sources of many diverse scaffolds, some of which
constitute a major class of antibiotics known to be generated on enzymatic assembly lines. For example,
fasamycins and naphthacemycins contain 1-phenylnaphthacene moiety, which is known to have a
rare carbon skeleton, and is a potent scaffold [3]. The gem-dimethyl tetracyclic carbon framework in
these compounds has been reported to show potent anti-methicillin-resistant Staphylococcus aureus
(MRSA) activities. Furthermore, fasamycins A and B were found to inhibit the FabF enzyme of type
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II fatty acid (FASII) biosynthesis in bacteria [4], while naphthacemycins showed inhibition against
several MRSA and methicillin-susceptible Staphylococcus aureus (MSSA) strains, in addition to an
efficient circumvention of β-lactam resistance when administered in combination with imipenem [5–7].
As part of our ongoing screening program to search for unique scaffolds, we have identified a cluster
of metabolites containing the rare phenylnaphthacene carbon framework from the soil bacterium,
Streptomyces sp. MA37, which is a prolific producer of natural products including legonmycins [8],
neocarazostatin A [9–11], legonoxamines [12], and a variety of organofluorines [13,14].
The current study establishes MS/MS molecular networks (MN) coupled with HPLC-UV-based
techniques for the rapid chemical dereplication and structural feature identification of metabolites
from complex crude microbial extracts of Streptomyces sp. MA37. The streamlined MN dereplication
process was performed via the online Global Natural Product Social (GNPS) Molecular Networking
platform [15,16]. Compounds with structurally-related motifs are clustered together in the network
based on a similarity in the mass spectra, including fragmentation patterns, and when coupled
with HPLC-UV, this provided an easy and rapid tool for the effective isolation of target scaffolds.
This technique is very important, since dereplication and subsequent identifications of known
motifs at an early stage in natural product research is a crucial step for the accelerated isolation
and characterization of new chemical scaffolds, thereby saving enormous amounts of time, effort,
and cost [17,18]. Subsequently, in the MA37 molecular network, a cluster of compounds was identified
that showed characteristic UV patterns (226, 250, 286, 355, and 420 nm), suggesting a common
chromophore [3,4,19]. Manual dereplication using AntiBase (2012) indicated that members of this
cluster have not been previously reported.
The isolation was carried out and afforded accramycin A 1. This molecule was named as such
due to the origin of the producer strain Streptomyces sp. MA37 from the Legon–Accra region in Ghana.
Using LC-MS, UV, 1D, and 2D NMR techniques, the structure of 1 was determined to be an aromatic
naphthacene-based natural product. When tested against Group B Streptococcus, accramycin A 1
showed a minimum inhibitory concentration (MIC) of 27 ug/mL. To our knowledge, this activity has
never been reported in any naphthacene-type congeners, suggesting that the accramycin scaffold could
be used as a basis for the development of potent drugs against Group B Streptococcus (GBS). Two further
accramycin analogues, 2 and 3 (Figures S10–S14) were also identified in fraction S3; however, they
were not isolable. Our results underline the enormous potential of the MS/MS molecular network
coupled with UV-based approaches to identify and target unprecedented scaffolds.
2. Results and Discussion
A large fermentation (12 L) of Streptomyces sp. MA37 was performed at 28 ◦C at 180 rpm for 7
days. Subsequently, Diaion®HP-20 (3 g/50 mL) was added to the fermentation culture and left to shake
overnight under the same incubation conditions. The mixture was filtered under vacuum, after which
the resin and mycelia were extracted with 100% methanol. The methanol extract was concentrated
under vacuum to give a total crude extract, followed by fractionation using Strata® C18-E solid phase
extraction (SPE), which yielded six fractions (S1–6). All the fractions obtained were subjected to HPLC
analysis with diode array detection to screen for metabolites bearing unique scaffolds. Fraction S3
showed the characteristic naphthacene UV spectra (226, 250, 286, 355, and 420 nm); hence, it was
selected for further fractionation using semi-preparative reversed-phase HPLC, resulting in the isolation
of accramycin A 1 (2.0 mg) (Figure 1).
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Figure 1. Structure of accra ycin (1) ith key BC (→) and NOESY (↔) correlations in DMSO-d6.
2.1. Structure Elucidation
Accramycin A 1 was obt ine as a yellow powder. It show d UV absorption maxima at 226, 250, 286,
355, and 420 nm, which is distinctive of a fasamycin or naphthacemycin co gener [5,19]. The olecular
formula of 1 (Figure 1) was established as C29H26O7 by HR ESIMS (cal ulated [M + H]+ = 487.1751;
observed [M + H]+ = 487.1741; ∆ = −2.1 ppm), indicating 17 d gre s of un aturation (Figures S1
and S2).
1H and 13C-NMR spectra and HSQC analysis revealed he pr ence of 29 carb s, including three
methyl carb ns at δC 20.6, 34.4, and 3 .7; two methoxy sig als at δC 55.3 and 55.6; seven sp2 methines
at δC 99.2, 104.0, 106.6, 106.9, 112.1, 115.8, and 121.7; on sp3 quaternary carbon at δC 39.3; and sixteen
sp2 quaternary carbons (δC 105.0–189.2) (Table 1, Figures S3–S9). Detailed analysis of the spectral data
sug ested that 1 was closely related to the previously describ d phthacene, fasamy in C [19].
Table 1. NMR data for accramycin A 1 (CD3OD, 600 MHz at 298 K).
Position 13C a 1H, mult. (J, Hz) Position 13C a 1H, mult. (J, Hz)
1 112.1, CH 6.49, d (2.4) 16 147.4, C -
2 167.0, C b - 17 39.3, C -
3 104.0, CH 5.99, d (2.4) 18 154.5, C -
4 167.1, C - 19 34.4, CH3 1.70, s
5 105.0, C - 20 34.7, CH3 1.69, s
6 189.2, C - 21 125.3, C -
7 107.4, C - 22 155.2, C -
8 165.3, C - 23 99.2, CH 6.32, d (2.4)
9 118.7, C - 24 160.2, C -
10 141.0, C b - 25 106.9, CH 6.37, d (2.4)
11 21.7, CH 6.71, d (2.4) 26 138.2, C -
12 161.1, C - 27 20.6, CH3 1.91, s
13 106.6, CH 7.19, d (2.4) 28 55.3, CH3 3.80, s
14 141.8, C - 29 55.6, CH3 3.95, s
15 115.8, CH 7.47, s
a Obtained from HSQC and HMBC, respectively; b estimated from DMSO-d6 spectrum.
The long-range couplings observed in the HMBC spectrum established the connectivity of
rings A–D. The cross-peaks from H-1 (δH 6.49) to C-3 (δC 104.0) and C-5 (δC 105.0) revealed a
2,4-dihydroxy-substituted benzene substructure (ring A). The cross-peaks from H3-19 (δH 1.70) and
H3-20 (δH 1.69) to C-16 (δC 147.4), C-17 (δC 39.3), and C-18 (δC 154.5) indicated a dimethyl motif
attached to carbon 17 (ring B), and connected to ring A via C-5 and C-18. Carbon 6 resonated at δC
189.2, which is consistent with a ketone moiety conjugated to two aromatic rings in the structure.
The cross-peaks from H-15 (δH 7.47) to C-7 (δC 107.4), C-9 (δC 118.7), and C-17 (δC 39.3) established the
nature of ring C, which was condensed to ring B via C-7 and C-16. H-11 (δH 6.71) and H-13 (δH 7.19)
in ring D were found to be arranged meta to one another based on their coupling constant (2.4 Hz).
The HMBC correlations from H3-29 (δH 3.95) to C-12 (δC 161.1), and H3-28 (δH 3.80) to C-24 (δC 160.2)
located the two methoxyl functions in rings D and E, respectively. Furthermore, ring E displayed two
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meta-coupled protons, H-23 (δH 6.32) and H-25 (δH 6.37, (J = 2.4 Hz), and an aromatic methyl group
(δH 1.91, H3-27). The arrangement of the different substituents within this aromatic ring was confirmed
by HMBC correlations from H3-27 to C-21 (δC 125.3), C-25 (δC 106.9), and C-26 (δC 138.2), and H-23 to
C-21, C-22 (δC 155.2), and C-24 (δC 160.2), while the attachment of ring E to the rest of the molecule
was established by the diagnostic correlation between H-11 and C-21.
The structure of 1 was further corroborated by analysis of the NOESY spectrum acquired in
DMSO-d6 (Figure 1) and by comparison with the MS and NMR data of fasamycins and naphthacemycins
in the literature [5,19], from which 1 differs with respect to the presence of a methoxy moiety (δH
3.95) attached to C-12 in ring D, thus establishing 1 as a new fasamycin congener, for which the name
accramycin A is proposed.
Two further accramycin derivatives, 2 and 3, were tentatively identified in the molecular network
(Figure S10) based on their UV spectra, but could not be isolated due to their minute quantities in
the extract. The typical chlorine isotope pattern observed for compound 2 (m/z 521.1319 ([M + H]+:
523.1282, 3:1, both consistent with the molecular formula C29H25ClO7)) in the MN cluster indicated that
it was a monochlorinated derivative of 1 (Figures S11 and S12). It is worth noting that chlorination is a
feature which is commonly observed in the fasamycin [19] and naphthacemycin [5] series. Compound
3 (m/z 535.1478 ([M + H]+: 537.1447, 3:1, both consistent with the molecular formula C30H27ClO7)) (m/z
535.1500 ([M + H]+, C30H28ClO7+)) was identified as a homologue of compound 2 (Figure S13–S14).
2.2. Proposed acc Biosynthetic Gene Cluster and Pathway
Given the structural similarity of accramycin A 1 with fasamycins [19], we predicted that 1 is
originated from polyketide Type II synthase. In silico analysis of the annotated MA37 genome using
antiSMASH 3.0 [20] revealed three putative type 2 PKS biosynthetic gene clusters. One biosynthetic
gene cluster (BGC) is likely to be involved in the biosynthesis of accramycins (acc) showing high
homology to the reported formicamycin BGC (KX859301) [19], and the other two share very high
sequence homology to FD-594 (AB469194.1) [21] or hexaricin (KT713752.1) [22] biosynthesis. A pairwise
comparison of the annotated proteins using BLAST [23] between the acc cluster with the formicamycin
BGC showed high amino acid identity, strongly supporting that the acc BGC most likely encodes the
biosynthesis of accramycins in MA37 (Table S1, Figure S15).
The acc gene cluster spans about 33 kb of genomic DNA and contains sixteen biosynthetic genes
with catalytic functions, three putative transport-related genes, and six possible regulatory genes with
deduced functions that were designated based on homology analysis (Figure 2A, Table 2). Thirteen
open reading frames (orf 1–13) in the BGC appear to have no catalytic functions in the biosynthesis of
1. It is likely that the minimal PKS containing KSα (AccA), KSβ (AccB), and ACP (AccC) catalyze the
decarboxylative condensation of one acetyl-CoA and twelve malonyl-CoAs to generate a tridecaketide
intermediate 4 (Figure 2B), followed by cyclization catalyzed by three cylase/aromatases (AccD, AccL,
and AccR) to yield 5. Further tailoring reactions occur through the action of additional putative
enzymes, including PKS hydrolase (AccX) and decarboxylase (AccY) to transform 5 to 6.
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Table 2. Deduced functions of open reading frames (ORFs) in accramycin (acc) biosynthetic gene cluster.
No. Gene Deduced Function No. Gene AA De uced Function
1 accE 242 DNA bindingresponse regulator 20 accL 119 Type II PKS cyclase
2 orf1 226 Synthase 21 accK 509 Na+/H+ exchanger
3 orf2 210 Glycosyl transferase 22 accJ 145 MarR familytranscriptional regulator
4 accM 220 SAM-dependentmethyl transferase 23 accG 359 Sensor histidine kinase
5 orf3 60 Hypothetical protein 24 accF 227 LuxR familyresponse regulator
6 orf4 U known 25 accD 152 Polyketide cyclase
7 ac N Transcriptional regulator 26 accC 97 Acyl car ier protein
8 ac O NAD(P)-d pendentoxidoreductase 27 accB 415 B ta-ketoacyl synthase
9 ac P MerR familytranscriptional regulator 28 accA 426 B ta-ketoacyl synthase
10 orf5 Nucleoside phosphorylase 29 accR 131 Cupin(cyclase/monooxygenase)
11 orf6 146 VOC family protein 30 accS 113 Antibiotic biosynthesismonooxygenase
12 orf7 202 Isomerase 31 accT 350 O-methyl transferase
13 accI 303 LysR familytranscriptional regulator 32 accU 113
Antibiotic biosynthesis
monooxygenase
14 orf8 108 Hypothetical protein 33 accV 430 Halogenase
15 orf9 140 Hypothetical protein 34 accW 348 O-methyl transferase
16 orf10 386 Molybdopterin-binding protein 35 orf12 480
Phenylalanine specific
permease
17 orf11 480 domain containing proteins 36 accX 777 hydrolase
18 accH 491 ABC ra sporter 37 orf13 43 DUF-1232 domaincontaining protein
19 accI 319 ABC transpo ter 38 accY 517 decarboxylase
Accramycin A 1 bears two methyl groups at position C-17 in the structure. This gem-dimethyl
moiety can be found in benastatins [24], resistomysin [25], napthacemycins [5], fasamycins [4],
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tetarimycin [26], and L-755,805 [27]. Three putative methyltransferases (AccM, AccT, AccW) were
identified in the acc gene cluster. AccM is closely related to BenF (42%/53%; CAM58795.1) [24,28]
which catalyzes the geminal bis-methylation step in benastatin biosynthesis, and is likely to involve
a similar PKS tailoring reaction in accramycin biosynthesis. The other two methyltransferases,
AccT and AccW, showed the highest homology to ForT and ForW (76%/83%, WP_098245764.1;
50%/60%, WP_098245767.1) in the formicamycin pathway, respectively, which are likely to encode the
O-methylation step of 1–3 at C-12 and C-24.
A further post-PKS transformation involved the halogenation of 1 to produce the minor metabolites
2 and 3. Analysis of the MA37 genome identified the putative FAD-dependent oxidoreductase AccV,
which shows high homology (68%/78%, WP_098245766.1) to ForV halogenase in formicamycin BGC [19]
Figure S14, Table S1), and is likely to catalyze the halogenation of 1, yielding 2 and 3.
2.3. Antibacterial Assay
Accramycin A 1 showed no activity against Gram-negative bacteria (Table 3). However, it
showed moderate activity (MIC 27 µg/mL) against Group B Streptococcus (GBS; Streptococcus agalactiae)
(Figure S16), and this activity has never been reported in any naphthacene-based antibiotics.
Table 3. Minimum inhibitory concentration (MIC) of accramycin A 1 against a panel of
bacterial pathogens.
Pathogen MIC (µg/mL)
Streptococcus B. ATCC 12386 27
Escherichia coli ATCC 25922 >50
Pseudomonas aeruginosa ATCC 27853 >50
GBS is the leading cause of life-threatening neonatal infections since 1970, and it also affects
pregnant women, the elderly, the immunocompromised, and those with underlying chronic medical
conditions [29,30]. The case fatality rate among adults has been reported to be markedly higher than
among neonates, and continues to climb over the last two decades [29–33].
GBS remains susceptible to penicillin; however, increasing MICs (4-fold to 8-fold higher) are now
described [33,34]. Reports have shown rising GBS resistance toward erythromycin and clindamycin,
ranging between 25–52% and 12–41%, respectively [29,33–36]. The first two cases of invasive
vancomycin-resistant GBS infection were documented in 2014 [37]. Continued investigation is
necessary to monitor this emerging threat. The growing incidence of antibiotic resistance reinforces the
need to develop alternative drugs.
The current study opens an avenue for possible structural modifications of the accramycin
pharmacophore for the development of potent drugs against GBS. Structure–activity relationship studies
on the accramycin scaffold would be of interest in the search for potential effective clinical candidates.
3. Materials and Methods
3.1. Fermentation
Streptomyces sp. MA37 was isolated from the rhizosphere of a Moracear Bark Cloth tree (Antiaris
toxicaria), growing in the Legon Botanical Gardens, Accra, Ghana, Africa [13]. The seed culture of
the MA37 strain was prepared by inoculating a single colony of the organism to 50 mL of ISP2 liquid
medium (Oxoid glucose 2.0 g, Oxoid yeast extract 2.0 g, VWR malt extract 5.0 g in 500 mL milliQ H2O),
and incubating for 7 days at 28 ◦C with shaking at 180 rpm (Incu-shake FL16-2). The seed culture was
used to inoculate 12.0 L of ISP2 broth (1:100) in 24 baﬄed flasks (CorningTM polycarbonate flasks),
each containing already autoclaved 500 mL of ISP2, and plugged with Fisherbrand™ polyurethane
foam stoppers (Fisher Scientific, UK). The cultures were incubated for 7 days maintained at 28 ◦C with
continuous agitation at 180 rpm. Subsequently, Diaion®HP-20 (3 g/50 mL) was added under sterile
Molecules 2019, 24, 3384 7 of 11
conditions to the fermentation culture and kept at the same temperature and shaking conditions for
18–24 h. The solution was filtered under vacuum, and the HP-20 resin was rinsed with milliQ water,
and extracted thrice with 100% methanol (Fisher Chemical HPLC grade). All the methanol extracts
were combined, concentrated under reduced pressure (Buchi Rotavapor R200, UK), and subjected to
LC high-resolution electrospray ionization mass spectrometry (LC HRESIMS, UK) analysis.
3.2. Extraction and Isolation
The crude methanol extract was fractionated on Strata® C18-E solid phase extraction (SPE) (55 µm,
70 Å, 20 g/60 mL) cartridges, and yielded 6 fractions (S1–6). Fractionation was performed using
10 column volumes of milliQ H2O (S1), 25% MeOH (S2), by 50% MeOH (S3), followed by 75% MeOH
(S4), and then 100% MeOH (S5). Finally, the SPE column was flushed with 100% MeOH with 0.05% of
trifluoroacetic acid (S6) (Acros Organics). All the eluents were concentrated under reduced pressure
(Buchi Rotavapor R200). Each fraction was subjected to LC-high-resolution electrospray ionization
mass spectrometry (HRESIMS) analysis.
HPLC-UV analysis was carried out in all the fractions (S1–6) to screen and target unique scaffolds
using an Agilent HPLC system (UK) (1260 Infinity) equipped with a diode array detector (DAD)
(C-18 ACE 10 µM 10 × 250 mm column) with spectral scanning between 200–550 nm. The compounds
of interest with the characteristic naphthacene UV maxima (226, 250, 286, 355, and 420 nm) were
observed in fraction S3.
Analysis of the HPLC/HRESIMS data of fraction S3 revealed three resolved peaks with [M + H]+
at m/z 487.1741, 521.1318, and 535.1500, respectively. Dereplication of these masses was achieved using
AntiBase (2012) software, indicating that all three molecules were previously unreported. Thus, fraction
S3 was selected for further fractionation by reversed-phase semi-prep (C18 ACE 10 µM 10 × 250 mm
column) HPLC (Agilent 1260 Infinity). The purification was carried out using a linear gradient from
20% H2O:MeOH:TFA (95:5:0.1) to 100% MeOH for 45 min with a solvent flow rate of 1.5 mL/min, to
yield accramycin A 1 (2.0 mg). Two further accramycin derivatives, 2 and 3 were identified in fraction
S3; however, they were not subjected to isolation due to their minute quantities in the extract.
Accramycin A 1: deep yellow powder. UV (CH3OH): 226, 250, 286, 355, and 420 nm; IR
(neat) νmax 3320 cm−1, 2945 cm−1, 2832 cm−1, 1650 cm−1, 1403 cm−1, 1111 cm−1, 1021 cm−1; 1H, 13C
NMR data, see Table 1; HRESIMS (positive mode) m/z calculated [M + H]+ = 487.1751; observed
[M + H]+ = 487.1741; ∆ = −2.1 ppm.
3.3. MS/MSMolecular Networking
The MS/MS data of the crude extract and fractions (S1–6) were converted from .RAW to .mzXML
file format using the ProteoWizard MSConvert software (version 3.0) ([38] for metabolite profiling and
the identification of new chemical entities in Streptomyces sp. MA37 extracts. The .mzXML files were
uploaded on the GNPS web platform to create the molecular network [15,39,40]. The GNPS settings
used to obtain the consensus spectra were: Precursor ion mass tolerance of 0.02 Da and fragment ion
tolerance of 0.02 Da. Edges were filtered by setting the default GNPS minimum cosine score above
0.7, minimum cluster size 2, network TopK 10, and more than 6 matched peaks. The spectral library
matching was performed with a similar cosine threshold and minimum matched peaks. The remaining
parameters were set as default, as suggested by the GNPS platform. The molecular network was
generated using the GNPS “Classic” molecular networking workflow (METABOLOMICS-SNETS-V2
version 1.2.5,), and the GraphML data obtained were visualized using the circular layout in Cytoscape
3.6.1 [41].
3.4. Spectroscopic Analysis
High Resolution Electro-spray Ionization Mass Spectrometry (HR-ESIMS) was obtained using a
LC MS Thermo Scientific MS system (LTQ Orbitrap) coupled to a Thermo Instrument HPLC system
(Accela PDA detector, Accela PDA autosampler and Accela Pump) on a positive ESI mode (30.000),
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MS/MS resolution 7500, C18 (Sunfire 150 × 46 mm column) Reversed phase separation using 0.1%
formic acid in water and 0.1% formic acid in acetonitrile gradient. The following conditions were used:
Capillary voltage 45 V, auxiliary gas flow rate 10–20 arbitrary units, capillary temperature 200 ◦C, sheath
gas flow rate 5 arbitrary units, spray voltage 4.5 kV, mass range 150–2000 amu (maximum resolution
30,000×). 1D and 2D NMR data were obtained on a Bruker AVANCE III HD 600 MHz (AscendTM14.1
Tesla, UK) with Prodigy TCITM cryoprobe at 298 K in DMSO-d6 and CD3OD. Trimethylsilane (TMS)
was used as an internal standard. Deuterated solvents were obtained from Goss Scientific. The infrared
spectrum was acquired using a PerkinElmer Spectrum version 10.4.00 Fourier transform infrared
(FTIR) spectrometer (2013) (UK) equipped with an Attenuated Total Reflection (ATR) diamond cell.
3.5. Antibacterial Assay
Minimum inhibitory concentrations (MIC) were determined following the antibacterial assay
protocols described in Lauritano (2016) [42] against the Gram-negative bacteria Escherichia coli (ATCC
25922), Pseudomonas aeruginosa (ATCC 27853), and the Gram-positive bacterium Streptococcus B (ATCC
12386). All bacteria were cultured in Mueller–Hinton broth. The assays were performed in serial
dilutions (in triplicates) in 96-well plates (Nunc, Thermo Fisher Scientific, United States), wherein a
50-µL suspension (log phase) of bacteria was incubated overnight at 37 ◦C and then supplemented
with 50 µL of the test extract. The positive control consisted of the bacteria plus Milli-Q water (no test
compound), while the negative control comprised the growth media and Milli-Q water. The absorbance
was recorded after 24 h (OD600) in a Victor3 multilabel plate reader. The growth medium appeared clear
in wells where the test compound prevented the growth or killed the bacteria; otherwise, it was cloudy.
Activity threshold was set below 0.05 (OD600). The MIC was defined as the lowest concentration of a
drug that inhibited visible bacterial growth.
4. Conclusions
With the rising GBS incidence and antibiotic resistance, we have yet to find more base scaffolds
for the development of alternate drugs and drug leads. Herein, we report the isolation of Accramycin
A 1 from the soil bacterium Streptomyces sp. MA37 by HPLC-UV aided by molecular networking.
The structure of 1 was deduced by analysis of the LC MS, UV, 1D, and 2D NMR, and identified as a new
naphthacene-type natural product. Preliminary studies on the antibacterial properties of 1 using GBS
showed an MIC of 27 µg/mL. This is the first report of GBS activity amongst the naphthacene-based
congeners, and suggests possible scaffold manipulation for the development of potent drugs against
GBS based on the accramycin framework. Two accramycin analogues, 2 and 3, were tentatively
identified in the MA37 fermentation broth by HPLC/HRESIMS analysis and molecular network.
A putative accramycin biosynthetic pathway was proposed.
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